Safer immunotherapy for cancer patients
Immunotherapy is revolutionizing cancer care. It is rapidly evolving from therapies that nonspecifically stimulate the immune system to more targeted ones that activate individual components of the immune system, increasing the efficacy of the treatment while decreasing toxicity.
Despite its tremendous success, immunotherapeutic agents are only successful in a subset of patients and we do not know what defines its success. At Asylia Diagnostics, we believe that high resolution molecular and proteomic tumor microenvironment profiling can shed light and help to stratify patients better. Contact us today to set up a meeting and learn more about partnering opportunities.
WHAT WE DO
At Asylia Diagnostics we are building a technology platform that will permit a quick and efficient high-resolution profiling of tumor microenvironment, different immune cells and their subtypes, and cell signaling. With the right data at hand, it will unlock an opportunity to discover novel biomarkers and modes of action for investigational drugs. Interested to learn more? Get in touch!
"Above all else, show the data."
Edward R. Tufte
GET IN TOUCH
JLABS @ BE, Janssen Pharmaceutica NV Beerse Site 1, Turnhoutseweg 30, 2340 Beerse, Belgium